April 3, 2012

One of the Russian pharmaceutical companies will soon release a new and unique form Ribavirin . This drug provides precise targeted delivery of special agents to target organs. To date, this medication does not have analogues in the world. To establish its release was possible thanks to the presence of the company's own design, protected by a patent.

By itself, ribavirin in medicine has been known for a long time - since the '70s of the last century. It is a viricide   with high efficiency. And when used in conjunction with Interferon   It is a classic treatment Hepatitis C . However, this substance has a serious disadvantage - the high toxicity. It just leads to a restriction of its use. But the drug still remains indispensable in the treatment of hepatitis C.

New drug includes liposomirovannuyu formula that sets it apart from the more traditional low toxicity. The essence of the formula is that ribavirin is liposomes   - Tiny bio bins. Shell nanoparticles is based on phospholipids Which, falling into blood They settle in certain organs, mainly in the liver, where it is released ribavirin.

It thus happens delivery of ribavirin in the liver, where effective treatment for hepatitis and necessary concentration of the substance. Furthermore, by reducing blood levels of free ribavirin in blood decreases its toxic effect on the body, which particularly affects the unequal cell system, brain, kidney, heart. As a result, there is a much better tolerability and lower severity of side effects.

The clinical and pre-clinical drug study showed that it has high efficiency, low toxicity, bioavailability.

Today the disease is included in the list of socially significant. Official statistics provides data showing that in Russia recorded 5-8 million. Man with hepatitis C. The main route of infection with this disease in Russia is considered to be the use of drugs by injection.